These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 11558698)

  • 1. Perspectives on the pharmaceutical industry.
    Reinhardt UE
    Health Aff (Millwood); 2001; 20(5):136-49. PubMed ID: 11558698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Will lower drug prices jeopardize drug research? A policy fact sheet.
    Light DW; Lexchin J
    Am J Bioeth; 2004; 4(1):W1-4. PubMed ID: 15035915
    [No Abstract]   [Full Text] [Related]  

  • 3. The Economics of Indication-Based Drug Pricing.
    Chandra A; Garthwaite C
    N Engl J Med; 2017 Jul; 377(2):103-106. PubMed ID: 28700848
    [No Abstract]   [Full Text] [Related]  

  • 4. Higher profile puts them in the crosshairs.
    Calandra R
    Manag Care; 2016 Dec; 25(12):28-29. PubMed ID: 28121556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The aspects of pricing policy in Azerbaijan pharmaceutical sector].
    Dzhalilova KI; Alieva KIa
    Georgian Med News; 2012 Jan; (202):48-53. PubMed ID: 22392783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The simple economics of risk-sharing agreements between the NHS and the pharmaceutical industry.
    Barros PP
    Health Econ; 2011 Apr; 20(4):461-70. PubMed ID: 21394816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmaceutical industry--prices and progress.
    Scherer FM
    N Engl J Med; 2004 Aug; 351(9):927-32. PubMed ID: 15329432
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmaceuticals in U.S. health care: determinants of quantity and price.
    Berndt ER
    J Econ Perspect; 2002; 16(4):45-66. PubMed ID: 15179978
    [No Abstract]   [Full Text] [Related]  

  • 9. Prescription drug prices in Canada.
    Gross D
    Issue Brief (Public Policy Inst (Am Assoc Retired Pers)); 2003 Jun; (IB62):1-22. PubMed ID: 12807123
    [No Abstract]   [Full Text] [Related]  

  • 10. American pharmaceutical prices.
    Alagona P
    Pharos Alpha Omega Alpha Honor Med Soc; 2002; 65(4):58. PubMed ID: 12592980
    [No Abstract]   [Full Text] [Related]  

  • 11. Prescription drug pricing: the consumer perspective.
    Searing A
    N C Med J; 2003; 64(6):300-2. PubMed ID: 14983625
    [No Abstract]   [Full Text] [Related]  

  • 12. Lowering Part D drug costs without direct CMS negotiations.
    Sipkoff M
    Manag Care; 2009 Sep; 18(9):11-2. PubMed ID: 19886203
    [No Abstract]   [Full Text] [Related]  

  • 13. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do pharmaceutical prices respond to potential patient out-of-pocket expenses?
    Pavenik N
    Rand J Econ; 2002; 33(3):469-87. PubMed ID: 12585303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Undermining Value-Based Purchasing - Lessons from the Pharmaceutical Industry.
    Dafny LS; Ody CJ; Schmitt MA
    N Engl J Med; 2016 Nov; 375(21):2013-2015. PubMed ID: 27732125
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmaceutical costs.
    Somberg JC
    J Clin Pharmacol; 1992 Dec; 32(12):1059. PubMed ID: 1487542
    [No Abstract]   [Full Text] [Related]  

  • 17. Exploring the rise in American pharmaceutical prices.
    Marwaha A
    Pharos Alpha Omega Alpha Honor Med Soc; 2002; 65(2):11-5. PubMed ID: 12099112
    [No Abstract]   [Full Text] [Related]  

  • 18. Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IV.
    Mullins CD; Seal B; Seoane-Vazquez E; Sankaranarayanan J; Asche CV; Jayadevappa R; Lee WC; Romanus DK; Wang J; Hay JW; Smeeding J
    Value Health; 2010; 13(1):18-24. PubMed ID: 19807903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmaceutical costs. An overview and analysis of legal and policy responses by the states.
    Latham SR
    J Leg Med; 2003 Jun; 24(2):141-73. PubMed ID: 12775406
    [No Abstract]   [Full Text] [Related]  

  • 20. Potential stifling effects of pharmaco-economics and regulatory policies.
    Data JL
    Am J Cardiol; 1998 Apr; 81(8A):34F-35F. PubMed ID: 9604904
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.